Glenmark Pharmaceuticals is currently trading at Rs. 1531.70, up by 14.50 points or 0.96% from its previous closing of Rs. 1517.20 on the BSE.
The scrip opened at Rs. 1510.80 and has touched a high and low of Rs. 1550.75 and Rs. 1501.50 respectively. So far 2765 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1830.05 on 15-Oct-2024 and a 52 week low of Rs. 766.65 on 15-Feb-2024.
Last one week high and low of the scrip stood at Rs. 1576.75 and Rs. 1447.00 respectively. The current market cap of the company is Rs. 42813.59 crore.
The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 36.30% and 17.06% respectively.
Glenmark Pharmaceuticals’ US-based subsidiary -- Glenmark Pharmaceuticals Inc, has launched Lacosamide Oral Solution, 10 mg/mL. Glenmark’s Lacosamide Oral Solution, 10 mg/mL is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat Oral Solution, 10 mg/mL of UCB, Inc. According to IQVIA sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of around $57.0 million.
Glenmark’s current portfolio includes 201 products authorized for distribution in the U.S. marketplace and 51 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to further enhance and accelerate the growth of its existing pipeline and portfolio.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1800.30 |
Dr. Reddys Lab | 1275.05 |
Cipla | 1472.05 |
Lupin | 2098.70 |
Zydus Lifesciences | 979.10 |
View more.. |